214 related articles for article (PubMed ID: 26328183)
1. What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?
Abdulmajed MI; Sancak EB; Reşorlu B; Al-Chalaby GZ
Turk J Urol; 2014 Dec; 40(4):228-32. PubMed ID: 26328183
[TBL] [Abstract][Full Text] [Related]
2. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
3. Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma.
Lee MY; Tsou MH; Cheng MH; Chang DS; Yang AL; Ko JS
World J Urol; 2000 Dec; 18(6):401-5. PubMed ID: 11204258
[TBL] [Abstract][Full Text] [Related]
4. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
5. Current concepts of tumor markers in bladder cancer.
Droller MJ
Urol Clin North Am; 2002 Feb; 29(1):229-34. PubMed ID: 12109349
[TBL] [Abstract][Full Text] [Related]
6. Current bladder tumor tests: does their projected utility fulfill clinical necessity?
Lokeshwar VB; Soloway MS
J Urol; 2001 Apr; 165(4):1067-77. PubMed ID: 11257640
[TBL] [Abstract][Full Text] [Related]
7. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
8. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
10. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
11. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of semaphorin 3A in patients with urothelial cancer.
Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
[TBL] [Abstract][Full Text] [Related]
13. [Urinary tumor marker for urothelial cancer].
Ohtani M; Iwasaki A; Shiraiwa H
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
[TBL] [Abstract][Full Text] [Related]
14. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
15. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
16. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic significance of protein NMP22 in bladder cancer].
Rybotycka Z; Długosz A
Pol Merkur Lekarski; 2015 Jun; 38(228):309-14. PubMed ID: 26098648
[TBL] [Abstract][Full Text] [Related]
18. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of urine NMP22 point-of-care test for the screening of bladder cancer].
Ihm CH; Kim JM; Sohn YH
Korean J Lab Med; 2007 Apr; 27(2):106-10. PubMed ID: 18094560
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]